Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for asthma
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on asthma or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on asthma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Bronchial thermoplasty for asthma Final Bronchial Thermoplasty for Asthma: Findings & Decision Page 1 of 3 Health Technology Clinical Committee Findings and Decision Topic: Bronchial Thermoplasty for Asthma Meeting Date: May 20, 2016 Final Adoption: July 8, 2016 Meeting materials and transcript are available on the HTA website: www.hca.wa.gov/hta/meetingmaterials/Forms/ExtMeetingMaterials.aspx Number and Coverage Topic: 20160520A – Bronchial Thermoplasty for Asthma HTCC Coverage Determination (...) : Bronchial thermoplasty for asthma is not a covered benefit. HTCC Reimbursement Determination: Limitations of Coverage: NA Non-Covered Indicators: NA Agency Contact Information: Agency Phone Number Labor and Industries 1-800-547-8367 Public Employees Health Plan 1-800-200-1004 Washington State Medicaid 1-800-562-3022 WA - Health Technology Assessment May 20, 2016 Final Bronchial Thermoplasty for Asthma: Findings & Decision Page 2 of 3 HTCC Coverage Vote and Formal Action: Committee Decision Based
Dexamethasone Versus Prednisone for Pediatric Asthma: Will the results take your breath away? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,400 family physicians, family medicine residents and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary (...) care research. www.acfp.ca May 9, 2016 Dexamethasone Versus Prednisone for Pediatric Asthma: Will the results take your breath away? Clinical Question: Are 1-2 doses of dexamethasone as effective as the standard five day prednisone regimen for treatment of pediatric asthma exacerbations? Bottom-line: Treatment of pediatric asthma exacerbations with short-course dexamethasone (0.6 mg/kg x 1-2 doses) is a safe and effective alternative to traditional five day courses of prednisone. For every ~20
Pills vs. Puffers: Leukotriene receptor antagonists for childhood asthma Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,000 family physicians, family medicine residents and medical students in Alberta. Established over fifty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research (...) . www.acfp.ca January 18, 2016 Pills vs. Puffers: Leukotriene receptor antagonists for childhood asthma Clinical Question: Are leukotriene receptor antagonists (LTRAs) effective in pediatric asthma? Bottom-line: Using leukotriene receptor antagonists instead of inhaled corticosteroids as monotherapy will lead to one more exacerbation in every 21 patients. As add-on to inhaled corticosteroids, leukotriene receptor antagonists are inferior to long acting beta-agonists (LABAs), and show similar outcomes
2014;60:99–107. 6 Kannan JA, Bernstein DI, Bernstein CK, Ryan PH, Bernstein JA, Villareal MS, Smith AM, Lenz PH, Epstein TG. Signi?cant predictors of poor quality of life in older asthmatics. Ann Allergy Asthma Immunol 2015;115:198–204. 7 Moorman JE, Akinbami LJ, Bailey CM, Zahran HS, King ME, Johnson CA, Liu X. National surveillance of asthma: United States, 2001- 2010. Vital Health Stat 3 2012;35:1–58. 8 Tsai CL, Lee WY, Hanania NA, Camargo CA Jr. Age-related differences in clinical outcomes (...) Evaluation and Management of Asthma in the Elderly AMERICANTHORACICSOCIETY DOCUMENTS AnOf?cialAmericanThoracicSocietyWorkshopReport:Evaluation andManagementofAsthmaintheElderly Gwen S. Skloot, Paula J. Busse, Sidney S. Braman, Elizabeth J. Kovacs, Anne E. Dixon, Carlos A. Vaz Fragoso, Nicola Scichilone, Y. S. Prakash, Christina M. Pabelick, Sameer K. Mathur, Nicola A. Hanania, Wendy C. Moore, PeterG.Gibson,SusanZieman,andBetinaB.Ragless;onbehalfoftheATSadhocCommitteeonAsthmaintheElderly
Asthma, Diagnosis and Management of Asthma, Diagnosis and Management of | ICSI The MN Health Collaborative includes physicians and other representatives from major healthcare organizations working together to address major health topics affecting Minnesota communities today. ICSI has been developing evidence-based clinical practice guidelines to improve patient care since 1993. ICSI helps forward-focused Minnesota health organizations find ways to redefine and redesign systems and the market (...) . Together, we aim to improve care and reduce costs for our patients, families and communities. e Guidelines Asthma, Diagnosis and Management of Revision Date: December 2016 / Eleventh Edition Endorsement Summary The ICSI Diagnosis and Management of Asthma guideline work group endorsed 2016 Global Strategy for Asthma Management and Prevention Report with added qualifications/comments. This report addresses the diagnosis and management of asthma in the pediatric and adult population. The GINA website
A repeated short educational intervention improves asthma control and quality of life We assessed the effectiveness of an asthma educational programme based on a repeated short intervention (AEP-RSI) to improve asthma control (symptom control and future risk) and quality of life. A total of 230 adults with mild-to-moderate persistent uncontrolled asthma participated in a 1-year cluster randomised controlled multicentre study. The AEP-RSI was given in four face-to-face sessions at 3-month (...) intervals, and included administration of a written personalised action plan and training on inhaler technique. Centres were randomised to the AEP-RSI (intervention) group or usual clinical practice group. Specialised centres using a standard educational programme were the gold standard group. A significant improvement in the Asthma Control Test score was observed in all three groups (p<0.001), but improvements were higher in the intervention and gold standard groups than in the usual clinical practice
Evaluation of Systemic Antioxidant Level and Oxidative Stress in Relation to Lifestyle and Disease Progression in Asthmatic Patients Asthma is a chronic disorder of the airways. Oxidative stress is an important part of asthma pathogenesis. It plays a crucial role in exacerbating the disease, as well as an important consequence of airways inflammation.The present study was undertaken to investigate the lipid peroxidation and catalase activity in serum and antioxidant level in plasma of asthmatic (...) patients and their association with lifestyle and severity of the disease.A total of 210 subjects, 120 asthmatics and 90 healthy controls matched in respect to age, sex, lifestyle and socioeconomic status, were chosen randomly for the present study. The samples were analyzed for MDA concentration and catalase activity in serum and ferric reducing ability of plasma (FRAP). Statistical analysis was done using unpaired Student's t-test, ANOVA with Duncan post hoc test and Pearson coefficient
Asthma and chronic obstructive pulmonary disease overlap syndrome: An update 27847903 2019 01 28 2450-131X 3 4 2015 Oct-Dec Journal of translational internal medicine J Transl Int Med Asthma and chronic obstructive pulmonary disease overlap syndrome: An update. 144-146 Lu Ming M Department of Respiratory Medicine, Peking University Third Hospital, Beijing 100191, China. Yao Wan-Zhen WZ Department of Respiratory Medicine, Peking University Third Hospital, Beijing 100191, China. eng Journal
Airway reactivity and sphingolipidsâ€”implications for childhood asthmaAsthma is a clinically heterogeneous disorder, whose onset and progression results from a complex interplay between genetic susceptibility, allergens, and viral triggers. Sphingolipids and altered sphingolipid metabolism have emerged as potential key contributors to the pathogenesis of asthma. Orosomucoid-like 3 gene (ORMDL3) and the asthma susceptibility locus 17q21 have been strongly and reproducibly linked to childhood (...) asthma, but how this gene is functionally linked to asthma is incompletely understood. ORMDL proteins play an integral role in sphingolipid homeostasis and synthesis, and asthma-associated ORMDL3 polymorphisms have been associated with early viral respiratory infections and increased risk of asthma. ORMDL proteins act as inhibitors of serine palmitoyl-CoA transferase (SPT), the rate-limiting enzyme for de novo sphingolipid synthesis, and decreased sphingolipid synthesis through SPT increases airway
The Impact of Bisphenol A and Phthalates on Allergy, Asthma, and Immune Function: A Review of Latest Findings In recent years, the impact of environmental exposure to chemicals and their immunological effects, including the development of allergy, has been a topic of great interest. Epidemiologic studies indicate that exposure to endocrine-disrupting chemicals produced in high volumes, including bisphenol A (BPA) and phthalates, is ubiquitous. The links between their exposure (...) and the development of allergy, asthma, and immune dysfunction have been studied in vitro, in vivo, and through human cohort studies. The purpose of this review is to examine the current body of research and to highlight deficits and strengths of current findings. Emerging science indicates that deleterious immunologic changes, including increased propensity to develop wheeze, allergy, and asthma after dietary and inhalation exposure to these chemicals, may be occurring.
Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations Short-term targeted treatment can potentially prevent fall asthma exacerbations while limiting therapy exposure.We sought to compare (1) omalizumab with placebo and (2) omalizumab with an inhaled corticosteroid (ICS) boost with regard to fall exacerbation rates when initiated 4 to 6 weeks before return to school.A 3-arm, randomized, double-blind, double placebo-controlled (...) , multicenter clinical trial was conducted among inner-city asthmatic children aged 6 to 17 years with 1 or more recent exacerbations (clincaltrials.gov #NCT01430403). Guidelines-based therapy was continued over a 4- to 9-month run-in phase and a 4-month intervention phase. In a subset the effects of omalizumab on IFN-α responses to rhinovirus in PBMCs were examined.Before the falls of 2012 and 2013, 727 children were enrolled, 513 were randomized, and 478 were analyzed. The fall exacerbation rate
[Omalizumab for the management of asthma] Omalizumab para el tratamiento del asma [Omalizumab for the management of asthma] Omalizumab para el tratamiento del asma [Omalizumab for the management of asthma] Ruano Gándara R, Rey-Ares L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation Ruano Gándara R, Rey-Ares L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A. Omalizumab para el tratamiento del asma. [Omalizumab for the management of asthma] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 440. 2015 Authors' objectives To assess the available evidence on the efficacy, safety and coverage related aspects regarding omalizumab in the management
A randomized, controlled, crossover study in patients with mild and moderate asthma undergoing treatment with traditional Chinese acupuncture. This study sought to verify the effects of acupuncture as an adjuvant treatment for the control of asthma.This was a randomized, controlled, crossover trial conducted at the Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. A total of 74 patients with mild/moderate, persistent asthma were randomized into two therapeutic groups (...) , induced sputum cell count, exhaled nitric oxide (NO) and with the Short Form 36 (SF-36) and Questionnaire on Quality of Life-Asthma (QQLA) questionnaires. Daily peak flow and symptom diaries were registered. The level of significance adopted was 5% (α=0.05).In Group B, after real acupuncture, there was a decrease in eosinophils (p=0.035) and neutrophils (p=0.047), an increase in macrophages (p=0.001) and an improvement in peak flow (p=0.01). After sham acupuncture treatment, patients experienced less
Anticholinergic vs Long-Acting Î²-Agonist in Combination With Inhaled Corticosteroids in Black Adults With Asthma: The BELT Randomized Clinical Trial. The efficacy and safety of long-acting β-agonists (LABAs) have been questioned. Black populations may be disproportionately affected by LABA risks.To compare the effectiveness and safety of tiotropium vs LABAs, when used with inhaled corticosteroids (ICS) in black adults with asthma and to determine whether allelic variation at the Arg16Gly locus (...) of the β2-adrenergic receptor (ADRB2) geneis associated with treatment response.A multisite (n = 20), open-label, parallel-group, pragmatic randomized clinical trial conducted from March 2011 through July 2013, enrolling black adults with moderate to severe asthma in the United States.Patients eligible for, or receiving, step 3 or step 4 combination therapy per National Heart, Lung, and Blood Institute guidelines, received ICS plus either once-daily tiotropium (n = 532) or twice-daily LABAs (n = 538
Diagnosis and management of asthma in preschoolers: A Canadian Thoracic Society and Canadian Paediatric Society position paper Asthma often starts before six years of age. However, there remains uncertainty as to when and how a preschool-age child with symptoms suggestive of asthma can be diagnosed with this condition. This delays treatment and contributes to both short- and long-term morbidity. Members of the Canadian Thoracic Society Asthma Clinical Assembly partnered with the Canadian (...) Paediatric Society to develop a joint working group with the mandate to develop a position paper on the diagnosis and management of asthma in preschoolers. In the absence of lung function tests, the diagnosis of asthma should be considered in children one to five years of age with frequent (≥8 days/month) asthma-like symptoms or recurrent (≥2) exacerbations (episodes with asthma-like signs). The diagnosis requires the objective document of signs or convincing parent-reported symptoms of airflow